Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection
Executive Summary
The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.
You may also be interested in...
Outgoing Merck CEO Touts COVID Innovations, But Worries Pandemic Prep May Lack Staying Power
Ken Frazier says advocates need to ensure governments continue investing in global biosecurity.
Keeping Track: First COVID Vaccine BLA Kicks Off; Oncology Submissions From Hutchmed, Takeda And Shorla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Coronavirus Update: J&J Vaccine On Pause Amid Reports Of Clots
The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.